Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank96
3Y CAGR+55.6%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+55.6%/yr
Quarterly compound
Percentile
P96
Near historical high
vs 3Y Ago
3.8x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.57% |
| Q3 2025 | 36.84% |
| Q2 2025 | 2.66% |
| Q1 2025 | -11.67% |
| Q4 2024 | 10.97% |
| Q3 2024 | 7.11% |
| Q2 2024 | -10.53% |
| Q1 2024 | 4.97% |
| Q4 2023 | -8.06% |
| Q3 2023 | -0.58% |
| Q2 2023 | -9.79% |
| Q1 2023 | 3.22% |
| Q4 2022 | 4.40% |
| Q3 2022 | -9.44% |
| Q2 2022 | 7.10% |
| Q1 2022 | 10.28% |
| Q4 2021 | -7.02% |
| Q3 2021 | -14.23% |
| Q2 2021 | -26.13% |
| Q1 2021 | -10.65% |
| Q4 2020 | -14.86% |
| Q3 2020 | -46.91% |
| Q2 2020 | -19.95% |
| Q1 2020 | 5.26% |
| Q4 2019 | -49.08% |
| Q3 2019 | -24.74% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |